Suchergebnisse - "Tabernero, J"

PubPharm (18)

1

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer : patient-reported outcomes from BEACON CRC

enthalten in: ESMO open | 2022

von Kopetz, S. | Grothey, A. | Van Cutsem, E. | +14

2

Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma : phase III RESOLVE study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2021

von Tempero, M. | Oh, D. | Tabernero, J. | +16

CommentIn: Ann Oncol. 2021 May;32(5):582-583. - PMID 33607222

3

Bevacizumab as adjuvant treatment of colon cancer : updated results from the S-AVANT phase III study by the GERCOR Group

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2020

von André, T. | Vernerey, D. | Im, S. | +18

4

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370) : a multicentre, open-label, phase 3, randomised, controlled trial

enthalten in: The Lancet. Oncology | 2019

von Eng, C. | Kim, T. | Bendell, J. | +77

CommentIn: Lancet Oncol. 2019 Jun;20(6):752-753. - PMID 31003912

5

Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2019

von Yoshino, T. | Portnoy, D. | Obermannová, R. | +19

6

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Tabernero, J. | Hozak, R. | Yoshino, T. | +15

CommentIn: Ann Oncol. 2018 Mar 1;29(3):527-529. - PMID 29360914

7

Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial

enthalten in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2017

von Longo-Muñoz, F. | Argiles, G. | Tabernero, J. | +8

8

Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Obermannová, R. | Van Cutsem, E. | Yoshino, T. | +14

9

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Ramanathan, R. | Goldstein, D. | Korn, R. | +10

CommentIn: Ann Oncol. 2016 Aug;27(8):1647-8. - PMID 27240995

10

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Chiorean, E. | Von Hoff, D. | Reni, M. | +14

CommentIn: Ann Oncol. 2016 Aug;27(8):1647-8. - PMID 27240995